Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mullen

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Cancer Research|July 30, 2009
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumabDana Faratian, Alexey Goltsov, Galina Lebedeva, et al.
Translational Oncology|September 19, 2024
Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabineDillum Patel, Alison L Dickson, Greice M Zickuhr, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2023
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agentJennifer Bré, Alison L Dickson, Oliver J Read, et al.
Journal of Visualized Experiments : Jove|February 6, 2013
The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancersFiach C O'Mahony, Jyoti Nanda, Alexander Laird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2011
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategiesDana Faratian, Annelien J M Zweemer, Yoko Nagumo, et al.
British Journal of Cancer|April 1, 2016
Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer modelsCarlos Martínez-Pérez, Carol Ward, Arran K Turnbull, et al.
Oncotarget|May 6, 2017
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cellsJames Meehan, Carol Ward, Arran Turnbull, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal CancerGrant D Stewart, Fiach C O'Mahony, Alexander Laird, et al.
Oncotarget|August 11, 2015
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer modelsCarol Ward, James Meehan, Peter Mullen, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Cancer Research|July 30, 2009
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumabDana Faratian, Alexey Goltsov, Galina Lebedeva, et al.
Translational Oncology|September 19, 2024
Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabineDillum Patel, Alison L Dickson, Greice M Zickuhr, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2023
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agentJennifer Bré, Alison L Dickson, Oliver J Read, et al.
Journal of Visualized Experiments : Jove|February 6, 2013
The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancersFiach C O'Mahony, Jyoti Nanda, Alexander Laird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2011
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategiesDana Faratian, Annelien J M Zweemer, Yoko Nagumo, et al.
British Journal of Cancer|April 1, 2016
Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer modelsCarlos Martínez-Pérez, Carol Ward, Arran K Turnbull, et al.
Oncotarget|May 6, 2017
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cellsJames Meehan, Carol Ward, Arran Turnbull, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal CancerGrant D Stewart, Fiach C O'Mahony, Alexander Laird, et al.
Oncotarget|August 11, 2015
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer modelsCarol Ward, James Meehan, Peter Mullen, et al.
Pageof 5